Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 4/2016

01-04-2016 | Nonstatin Drugs (E. deGoma, Section Editor)

Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity

Authors: L. I. Igel, A. Sinha, K. H. Saunders, C. M. Apovian, D. Vojta, L. J. Aronne

Published in: Current Atherosclerosis Reports | Issue 4/2016

Login to get access

Abstract

Metformin is not currently used for weight loss or diabetes prevention because it lacks an FDA indication for obesity and/or pre-diabetes treatment. Based on the evidence, metformin has been shown to decrease the incidence of type 2 diabetes, and compares favorably to other weight-loss medications in terms of efficacy as well as safety. Thus, metformin should be considered for a treatment indication in patients with these conditions.
Literature
1.
2.
3.
Centers for Disease Control and Prevention. National Diabetes Statistics Report: estimates of diabetes and its burden in the United States, 2014. Atlanta: U.S. Department of Health and Human Services; 2014.
4.
Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer- and service-specific estimates. Health Aff. 2009;28(5):w822–31.CrossRef
5.
Matthew Kasman, Ross A. Hammond, Aurite Werman, Austen Mack-Crane and RAM. Brookings Institution: An in-depth look at the lifetime economic costs of obesity; 2015
6.
Moin T, Li J, Duru OK, et al. Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study. Ann Intern Med. 2015;162(8):542–8.CrossRefPubMedPubMedCentral
7.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement—executive summary. Endocr Pract. 2013;19(3):536–57.CrossRefPubMedPubMedCentral
8.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–65.CrossRef
9.
10.
Schultes B, Oltmanns KM, Kern W, Fehm HL, Born J, Peters A. Modulation of hunger by plasma glucose and metformin. J Clin Endocrinol Metab. 2003;88(3):1133–41.CrossRefPubMed
11.
Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(1):27–31.PubMed
12.
Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes. 2014;7:241–53.PubMedPubMedCentral
13.•
Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35(4):731–7. This study examined the effect of metformin on weight loss in the Diabetes Prevention Program Outcome Study (DPPOS). It demonstrated that weight loss was related to adherence to metformin, and was durable for at least 10 years of treatment.CrossRef
14.••
Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62. This publication denotes the first clinical practice guidelines for the pharmacological management of obesity. These guidelines were drafted by an Endocrine Society-appointed task force of experts, and were co-sponsored by the European Society of Endocrinology and The Obesity Society.CrossRefPubMed
15.
Li D-J, Huang F, Lu W-J, Jiang G-J, Deng Y-P, Shen F-M. Metformin promotes irisin release from murine skeletal muscle independently of AMP-activated protein kinase activation. Acta Physiol (Oxf). 2015;213(3):711–21.CrossRef
16.
Kim Y-W, Kim J-Y, Park Y-H, et al. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes. 2006;55(3):716–24.CrossRefPubMed
17.
Aubert G, Mansuy V, Voirol M-J, Pellerin L, Pralong FP. The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism. 2011;60(3):327–34.CrossRefPubMed
18.
Glueck CJ, Fontaine RN, Wang P, et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001;50(7):856–61.CrossRefPubMed
19.
Kusaka I, Nagasaka S, Horie H, Ishibashi S. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability? Diabetes Obes Metab. 2008;10(11):1039–46.CrossRefPubMed
20.
Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001;24(3):489–94.CrossRefPubMed
21.
Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):323–9.CrossRefPubMed
22.
Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother. 2008;42(6):817–26.CrossRefPubMed
23.
24.
Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care. 1996;19(9):920–6.CrossRefPubMed
25.
Paolisso G, Amato L, Eccellente R, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest. 1998;28(6):441–6.CrossRefPubMed
26.
Malin SK, Nightingale J, Choi S-E, Chipkin SR, Braun B. Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults. Obesity (Silver Spring). 2013;21(1):93–100.CrossRef
27.
Peirson L, Douketis J, Ciliska D, Fitzpatrick-Lewis D, Ali MU, Raina P. Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis. C open. 2014;2(4):E306–17.CrossRef
28.•
Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change—a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363–70. The authors completed a systematic review and meta-analysis of 54 commonly precribed drugs to summarize the evidence about their association with weight change. Weight loss was associated with the use of metformin (1.1 kg), acarbose (0.4 kg), miglitol (0.7 kg), pramlintide (2.3 kg), liraglutide (1.7 kg), exenatide (1.2 kg), zonisamide (7.7 kg), topiramate (3.8 kg), bupropion (1.3 kg), and fluoxetine (1.3 kg).CrossRefPubMed
29.
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefPubMed
30.
Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–86.CrossRefPubMed
31.
32.
Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35(4):723–30.CrossRef
33.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):854–65.
34.
Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169(6):616–25.CrossRefPubMed
35.
Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304–11.CrossRefPubMedPubMedCentral
36.
Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRefPubMed
37.
Fonseca V, McDuffie R, Calles J, et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care. 2013;36(8):2162–8.CrossRefPubMedPubMedCentral
38.
Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–8.CrossRefPubMed
39.
Chan JC, Tomlinson B, Critchley JA, Cockram CS, Walden RJ. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care. 1993;16(7):1035–8.CrossRefPubMed
40.
DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541–9.CrossRefPubMed
41.
Ravn P, Haugen AG, Glintborg D. Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. Minerva Endocrinol. 2013;38(1):59–76.PubMed
42.
Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–92.CrossRefPubMed
43.
Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005;90(8):4593–8.CrossRefPubMed
44.
Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356(6):551–66.CrossRefPubMed
45.
Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism. 1999;48(4):511–9.CrossRefPubMed
46.
Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M. Body composition is improved during 12 months’ treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab. 2014;99(7):2584–91.CrossRefPubMed
47.
Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab. 2014;99(5):1870–8.CrossRefPubMedPubMedCentral
48.
Hasnain M, Vieweg WVR, Fredrickson SK. Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions—ProQuest. CNS Drugs. 2010;24(3):193–206.CrossRefPubMed
49.
G. Fiedorowicz J, D. Miller D, R. Bishop J, A. Calarge C, L. Ellingrod V, G. Haynes W. Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatry Rev. 2012;8(1):25–36.CrossRef
50.
Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand. 1999;100(1):3–16.CrossRefPubMed
51.
Jesus C, Jesus I, Agius M. A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics. Psychiatr Danub. 2015;27 Suppl 1:S489–91.PubMed
52.
Wu R-R, Zhao J-P, Guo X-F, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008;165(3):352–8.CrossRefPubMed
53.
Wu R-R, Zhao J-P, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185–93.CrossRefPubMed
54.
Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170(9):1032–40.CrossRefPubMed
55.
Björkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2011;25(3):299–305.CrossRefPubMed
56.
57.•
Goodwin PJ, Parulekar WR, Gelmon KA, et al. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst. 2015;107(3):djv006. This study examined the effects of metformin on metabolic factors in patients with breast cancer. The NCIC Clinical Trials Group (NCIC CTG) illustrated that metformin improved weight, insulin, glucose, leptin, and CRP at six months.CrossRefPubMedPubMedCentral
58.
Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med. 2011;123(1):15–23.CrossRefPubMed
59.
De Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181.CrossRefPubMedPubMedCentral
60.
Rasuli P, Hammond DI. Metformin and contrast media: where is the conflict? Can Assoc Radiol J. 1998;49(3):161–6.PubMed
61.
Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;1:CD002967.PubMed
62.
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–75.CrossRefPubMedPubMedCentral
63.•
Flory JH, Hennessy S. Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on food and drug administration contraindications. JAMA Intern Med. 2015;175(3):458–9. The authors propose use of estimated glomerular filtration rates (eGFRs) as a better measure of renal function than serum creatinine levels in determining contraindications to metformin use, and suggest that the FDA revisit metformin’s current contraindication in patients with mild renal insufficiency.CrossRefPubMed
Metadata
Title
Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity
Authors
L. I. Igel
A. Sinha
K. H. Saunders
C. M. Apovian
D. Vojta
L. J. Aronne
Publication date
01-04-2016
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 4/2016
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-016-0568-3

Other articles of this Issue 4/2016

Current Atherosclerosis Reports 4/2016 Go to the issue

Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)

Testosterone Replacement Therapy and the Cardiovascular System

Statin Drugs (B. Wiggins, Section Editor)

Gemfibrozil in Combination with Statins—Is It Really Contraindicated?

Nonstatin Drugs (E. deGoma, Section Editor)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics

Genetics (A. Marian, Section Editor)

Epigenetics and Peripheral Artery Disease

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits